The present invention relates to a process for preparing CCR3 inhibitors of formula (1), wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alkyl; Xis an anion selected from the group consisting of chloride or ? dibenzoyltartrate; j is 1 or 2.
-
Page/Page column 13-14
(2013/10/22)
PROCESS FOR THE MANUFACTURING OF CRR INHIBITORS
The present invention relates to a process for preparing CCR3 inhibitors of formula 1, wherein R1 is H, C1-6-alkyl, C0-4-alkyl-C3-6-cycloalkyl, C1-6-haloalkyl; R2 is H, C1-6-alky
-
Paragraph 0091
(2013/10/08)
CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS
This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.
-
Page/Page column 8
(2012/10/23)
CO-CRYSTALS AND SALTS OF CCR3-INHIBITORS
This invention relates to co-crystals and salts of CCR3 inhibitors of formula (1), pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.
-
Page/Page column 23
(2012/04/23)
SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS
Object of the present invention are novel substituted compounds of the formula 1, wherein A, R1, R2, R3 and R4 are defined as in the description. Another object of the present invention is to provide antagonists of CCR3, more particularly to provide pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of at least one of the compounds of the present invention or a pharmaceutically acceptable salt thereof.
-
Page/Page column 40
(2010/11/03)
More Articles about upstream products of 1251529-11-9